Selected data models

You must log in to select data models for download or further analysis.

18 Search results.
Relevance Rating New first Old first

ICHOM Lung Cancer - Baseline - Clinical Form

- 4/30/20 - 1 form, 5 itemgroups, 14 items, 1 language
Itemgroups: Administrative data, Demographic factors, Baseline Clinical Factors, Baseline tumor factors, Degree of health
ICHOM Lung cancer data collection Version 2.3.1 Revised: April 10th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. For Lung Cancer, the following conditions and treatment approaches (or interventions) are covered by our Standard Set. Conditions: Small Cell and Non-Small Cell Lung Cancer Treatment Approaches: Surgery | Radiotherapy | Chemotherapy | Targeted Therapy | Immunotherapy | Other This document contains Baseline - Clinical Form. It depicts first doctor's visit. Collecting Patient-Reported Outcome Measures: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire (EORTC QLQ-LC13). Both are free for all health care organizations, but a license is needed for use. http:// groups.eortc.be/qol/eortc-qlq-c30 is the official distribution site for EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaire. Therefore only the total score will be included in this version of the standard set. Publication: Mak KS, van Bommel AC, Stowell C, et al. Defining a standard set of patient-centred outcomes for lung cancer. Eur Respir J. 2016;48(3):852–860. doi:10.1183/13993003.02049-2015 For this standard set ICHOM was supported by the Alliance of Dedicated Cancer Centers. For this version of the standard set, semantic annotation with UMLS CUIs has been added.

ICHOM Lung Cancer - Baseline - Patient-Reported Form

- 4/30/20 - 1 form, 4 itemgroups, 22 items, 1 language
Itemgroups: Administrative Data, Demographic factors, Baseline Clinical factors, Degree of health
ICHOM Lung cancer data collection Version 2.3.1 Revised: April 10th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. For Lung Cancer, the following conditions and treatment approaches (or interventions) are covered by our Standard Set. Conditions: Small Cell and Non-Small Cell Lung Cancer Treatment Approaches: Surgery | Radiotherapy | Chemotherapy | Targeted Therapy | Immunotherapy | Other This document contains the Baseline - Patient-Reported Form. It depicts first doctor's visit. Collecting Patient-Reported Outcome Measures: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire (EORTC QLQ-LC13). Both are free for all health care organizations, but a license is needed for use. http:// groups.eortc.be/qol/eortc-qlq-c30 is the official distribution site for EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires. Therefore only the total score will be included in this version of the standard set. Publication: Mak KS, van Bommel AC, Stowell C, et al. Defining a standard set of patient-centred outcomes for lung cancer. Eur Respir J. 2016;48(3):852–860. doi:10.1183/13993003.02049-2015 For this standard set ICHOM was supported by the Alliance of Dedicated Cancer Centers. For this version of the standard set, semantic annotation with UMLS CUIs has been added.

Lung Cancer NCT01336894 Toxicity - ACOSOG-Z4099 Baseline Adverse Event Form - 3177833v1.0 - ACOSOG-Z4099 Baseline Adverse Event Form

- 1/9/15 - 1 form, 3 itemgroups, 10 items, 1 language
Itemgroups: Header Module, Visit, Required Baseline Adverse Events from Section 8 of Protocol
ACOSOG-Z4099 Baseline Adverse Event Form Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9805AE2C-90B9-70EF-E040-BB89AD431611

Lung Cancer NCT00738881 On-Study - North Central Cancer Treatment Group Baseline CD Submission Form - 2731639v1.0 - North Central Cancer Treatment Group Baseline CD Submission Form

- 1/8/15 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: Header Module, Header, Completed by VIEW Personnel:
North Central Cancer Treatment Group Baseline CD Submission Form Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=46FF5830-748C-163A-E044-0003BA3F9857

Lung Cancer NCT00738881 Treatment - North Central Cancer Treatment Group N0723 Concurrent Treatment Form - Baseline - 2731645v1.0 - North Central Cancer Treatment Group N0723 Concurrent Treatment Form - Baseline

- 1/8/15 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Header, Header
North Central Cancer Treatment Group N0723 Concurrent Treatment Form - Baseline Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=46FF63E8-1051-1831-E044-0003BA3F9857

Lung Cancer NCT00738881 Toxicity - North Central Cancer Treatment Group N0723 Baseline Adverse Events Form - 2731396v1.0 - North Central Cancer Treatment Group N0723 Baseline Adverse Events Form

- 1/8/15 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Header Module, Required Baseline Adverse Events from Section 10.0 of Protocol
North Central Cancer Treatment Group N0723 Baseline Adverse Events Form Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=46FC7080-5A71-1051-E044-0003BA3F9857

NSCLC (NCT00049543) - Eligibility Checklist and Initial Evaluation NSCLC (NCT00049543)

- 9/20/21 - 1 form, 10 itemgroups, 154 items, 1 language
Itemgroups: PATIENT INFORMATION, ELIGIBILITY CHECKLIST, RANDOMIZATION, HISTORY AND PHYSICAL EXAM, INVESTIGATIONS, HEMATOLOGY and BIOCHEMISTRY (baseline), DISEASE HISTORY and PRIOR TREATMENT, Adverse event, CONCOMITANT MEDICATIONS, OTHER MAJOR MEDICAL PROBLEMS
Form 1 - Eligibility Checklist and Initial Evaluation Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed NCT00049543 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A7422C05-78BD-5678-E034-0003BA0B1A09

Southwest Oncology Group Baseline Tumor Assessment Form

- 7/3/15 - 1 form, 4 itemgroups, 19 items, 1 language
Itemgroups: SWOG clinical trial administrative data, Tumor assessment, Comments, CCRR MODULE
Southwest Oncology Group Baseline Tumor Assessment Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A50B77BD-3730-1660-E034-080020C9C0E0

E5508 Baseline Disease Evaluation Form (RECIST 1.1) NCT01107626

- 6/16/15 - 1 form, 7 itemgroups, 26 items, 1 language
Itemgroups: Header Module, Data amendment, TARGET LESIONS, TARGET LESIONS - NON NODAL, TARGET LESIONS - NODAL, NONTARGET LESIONS, Comments
E5508 Baseline Disease Evaluation Form (RECIST 1.1) NCT01107626 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6D42B202-CDD6-89E9-E040-BB89AD430258

Southwest Oncology Group S0819 Baseline Tumor Assessment Form NCT00946712

- 6/9/15 - 1 form, 4 itemgroups, 21 items, 1 language
Itemgroups: Header, Evaluation of lesions, Diagnostic test, COMMENTS
Southwest Oncology Group S0819 Baseline Tumor Assessment Form NCT00946712 Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=684CF883-62F5-1929-E040-BB89AD4373A3

ECOG4599 Baseline Disease Evaluation Form (RECIST)

- 5/28/15 - 1 form, 1 itemgroup, 27 items, 1 language
Itemgroup: Baseline Disease Evaluation Data
ECOG4599 Baseline Disease Evaluation Form (RECIST) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A1317E8C-0271-4779-E034-080020C9C0E0

BASELINE TUMOR ASSESSMENT FORM NCT00020709

- 6/3/15 - 1 form, 4 itemgroups, 23 items, 1 language
Itemgroups: SWOG clinical trial administrative data, Target lesion status, Tests, Notes
BASELINE TUMOR ASSESSMENT FORM NCT00020709 S0023: Combination Chemo Plus RT With or Without Gefitinib in Treating Patients With Unresectable Stage III NSCLC Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9CA62D43-4831-361C-E034-080020C9C0E0

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial